Information Provided By: 
Fly News Breaks for September 14, 2018
ARWR
Sep 14, 2018 | 07:47 EDT
Jefferies analyst Maury Raycroft raised his price target for Arrowhead Pharmaceuticals to $24 after the company last week reported initial ARO-HBV data at the World Gastroenterologists Summit. The update was unexpected and an early glimpse into what should be a more mature, robust dataset at the American Association for the Study of Liver Diseases meeting, Raycroft tells investors in a research note. He sees the de-risking as a positive and keeps a Buy rating on Arrowhead.
News For ARWR From the Last 2 Days
There are no results for your query ARWR
